ArticleFrontiers in medicine2026
Low-dose daratumumab and bortezomib for the treatment of proliferative glomerulonephritis with monoclonal immunoglobulin deposits: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is an exceptionally rare glomerular disease, accounting for only 0.17-3.7% of all renal biopsies, and no consensus-based treatment algo-rithm has been established. Although daratumumab, a humanized anti-CD38 monoclonal antibody, has shown promising efficacy in PGNMID, the existing evidence is limited to small case series using standard-dose regimens (16 mg/kg). Critically, data on reduced-dose daratumumab in elderly patients with CyBorD-refractory disease and multiple comorbidities remain scarce. This case report adds to the limited experience with a reduced-dose strategy in a high-risk elderly patient with CyBorD-refractory PGNMID. Case presentation: A 73-year-old Chinese male with biopsy-proven PGNMID (IgG3- Conclusion: This case suggests that low-dose daratumumab combined with bortezomib may be a feasible and apparently well-tolerated salvage option in this selected patient with CyBorD-refractory PGNMID and a heavy comorbidity burden. The favourable outcome in this single case raises the possibility that dose de-escalation might preserve efficacy while mitigating toxicity, although this hypothesis requires confirmation in larger studies. This report adds to the limited global evidence for daratumumab in PGNMID and highlights the need for personalized, risk-stratified dosing strategies in this rare and challenging glomerulopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.